Aegis Sciences Corporation Executive and Leadership Team

Donald Standridge, the Chief Executive Officer & Co-Founder at Aegis Sciences Corporation, directs the long-term vision and strategic growth of the organization. By prioritizing innovation in drug testing methodologies, Standridge ensures the company maintains a leadership position within the diagnostic health services sector. This executive role involves cultivating partnerships with pain management providers and behavioral health professionals to expand the reach of adherence monitoring services. Through the oversight of high-level corporate initiatives, Standridge drives the development of advanced analytical tools like the Aegis NPS Insights Dashboard. Donald Standridge also collaborates with the Board to align operational capabilities with evolving market demands for substance use disorder treatment support. By fostering a culture of scientific excellence, Standridge secures the company's reputation as a premier independent anti-doping laboratory, ultimately enhancing patient care standards across diverse clinical environments throughout the nation.

Joel Galanter, the Interim Chief Executive Officer at Aegis Sciences Corporation, manages the immediate operational continuity and strategic execution of the firm. Galanter focuses on stabilizing core business functions while maintaining the high standards required for oral fluid and urine analysis services. This leadership position involves coordinating with department heads to ensure seamless delivery of diagnostic insights to sports organizations and clinical providers. By streamlining internal processes, Galanter optimizes the efficiency of laboratory operations and service delivery models. Joel Galanter also monitors emerging drug trends to ensure the company remains at the forefront of the diagnostic industry. Through rigorous management of organizational resources, Galanter supports the ongoing mission of providing objective measures for substance use. This role requires constant engagement with stakeholders to uphold the integrity of testing protocols and ensure compliance across all regional operations within the United States.

Beverly Cawthon, the Chief Operating Officer at Aegis Sciences Corporation, architects the daily operational workflows and service delivery systems that define the company's diagnostic capabilities. Cawthon oversees the logistical execution of comprehensive drug testing, ensuring that laboratory processes meet the stringent requirements of pain management and behavioral health clients. By managing the integration of advanced testing methods, Cawthon drives improvements in turnaround times and diagnostic accuracy. This leadership role involves supervising cross-functional teams to maintain high-quality standards across all testing facilities. Beverly Cawthon also implements scalable operational strategies to support the expansion of services into new clinical markets. Through the optimization of resource allocation and supply chain management, Cawthon ensures that the organization remains responsive to the needs of healthcare providers. This focus on operational excellence directly impacts the ability of the company to provide reliable data for patient care and substance use disorder treatment.

Tim Ryan, the Chief Information Officer at Aegis Sciences Corporation, directs the digital infrastructure and data management systems essential for modern diagnostic services. Ryan architects secure platforms that facilitate the delivery of critical drug testing results to healthcare providers and sports organizations. By overseeing the development of the Aegis NPS Insights Dashboard, Ryan enables the tracking of emerging drug trends through sophisticated data analytics. This leadership role involves protecting sensitive patient information while ensuring high availability of diagnostic reporting tools. Tim Ryan also manages the integration of new software solutions to enhance the efficiency of laboratory information systems. Through the implementation of robust cybersecurity measures, Ryan safeguards the integrity of the company's digital assets. This focus on technological innovation supports the broader mission of providing objective measures for substance use, ensuring that clinical partners receive timely and actionable data to improve patient outcomes.